Dr. Oh gives overview of oligometastatic prostate cancer and emergent therapies

Video

“We have new therapies, both AR-targeted therapies, as well as the use of SBRT, or targeted radiotherapy, that have changed the landscape,” says William K. Oh, MD.

In this video, William K. Oh, MD, discusses why oligometastatic prostate cancer is a “hot topic” in urology right now, and what therapies are expected to emerge in the near future to help manage this complex disease state. These concepts stem from Oh’s presentation, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.

Related Videos
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
Paul E. Dato, MD, an expert on prostate cancer
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
Charles Parker, MD, answers a question during a Zoom video interview
Related Content
Studies explore resistance to hormone therapy in prostate cancer

Studies explore resistance to hormone therapy in prostate cancer

December 6th 2023
Article

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

Urology Times Speaking of Urology® logo

Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer

March 23rd 2023
Podcast

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

Receipt of hormone therapy is lacking among Black men with prostate cancer

Receipt of hormone therapy is lacking among Black men with prostate cancer

December 4th 2023
Article

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

Dr. Laviana on decisional regret after prostate cancer treatment

Dr. Laviana on decisional regret after prostate cancer treatment

June 28th 2022
Podcast

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

NCCN awards funding to 4 advanced prostate cancer research projects

NCCN awards funding to 4 advanced prostate cancer research projects

November 24th 2023
Article

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

Benjamin H. Lowentritt, MD, FACS, an expert on prostate cancer

Prostate Cancer Treatment: Incorporating Micronized Abiraterone into Clinical Practice

November 17th 2023
Article

In the second article of this series, Benjamin H. Lowentritt, MD, FACS, provides clinical insights on micronized abiraterone as a treatment for patients with prostate cancer.

© 2023 MJH Life Sciences

All rights reserved.